Pharmaceutical industry
BioQuest, Inc. has formed a strategic partnership with Biovector Therapeutics S.A. to evaluate and develop a therapeutic vaccine candidate for HIV. The collaboration focuses on the evaluation of a potential protective HIV vaccine, leveraging BioQuest's licensed technology from The University of Texas, M.D. Anderson Cancer Center,
Pharmaceutical industry
BioQuest Inc. and Biovector Therapeutics S.A. have announced a partnership to cooperate in the evaluation and development of an HIV vaccine candidate. The agreement aims to create a therapeutic immune system stimulant capable of fighting HIV infection in infected individuals and potentially serving as a protective vaccine. The partnership
Pharmaceutical industry
North American Vaccine, Inc. (Amex: NVX) has announced that it is continuing talks with Baxter International Inc. regarding the Share Exchange Agreement. The parties have agreed to a third extension of the company's credit facility with the Bank of America, pushing the due date to April 12, 2000.
Pharmaceutical industry
AIDS vaccines could include inactivated Tat toxoid, an antigen capable of inducing antibodies against the HIV Tat protein, according to Robert C. Gallo, a pioneer in AIDS research. Preliminary results from studies at Gallo's Institute of Human Virology indicate that the chemically detoxified toxin is safe and immunogenic
Pharmaceutical industry
The U.S. Food and Drug Administration (FDA) has granted permission to Amerimmune, Inc. to test its revolutionary treatment Cytolin in a Phase I/II study in HIV-infected individuals. The study aims to evaluate the safety, tolerability, and efficacy of Cytolin, a patented monoclonal antibody that blocks certain adhesion molecules
Drugs
Peter Sears, a renowned expert in corporate investing and venture capital, has joined the board of directors of AVANT Immunotherapeutics, Inc. Sears has an impressive track record of investing in emerging biomedical companies, with S.R. One, the venture capital fund he founded in 1985, investing nearly a quarter of
Drugs
Scientists at Roche and Gilead Sciences are on the cusp of a major medical breakthrough with the submission of a new drug application to the FDA for a pill designed to treat all common strains of the flu. The innovative medication, GS4104, targets the neuraminidase protein, a key site of
Pharmaceutical industry
Researchers have identified a potential breakthrough in treating stroke patients using the venom from a tropical snake. A recent study found that nearly 42% of elderly stroke patients who received the experimental drug ancrod, made from Malayan pit viper venom, were either completely or almost completely back to normal after
Pharmaceutical industry
Axys Pharmaceuticals, a leader in the integration of life science technologies, and Protein Design Labs, a developer of humanized and human antibodies, have announced an agreement to discover compounds that interact with key cellular signaling pathways. The collaboration will leverage Axys' diverse small molecule library and PDL's
